Harbinger Health

Executive Summary

Harbinger Health is a private diagnostics company headquartered in Cambridge, Massachusetts, founded in 2020 with a mission to transform cancer detection. Current diagnostic tools identify only a few cancer types and often at advanced stages when outcomes are poor. Harbinger aims to develop a blood-based, multi-cancer early detection (MCED) test that leverages insights from aging biology and machine learning to identify cancer signals earlier and more accurately. Backed by Flagship Pioneering, the company has raised significant capital to advance its proprietary platform, which focuses on analyzing circulating biomarkers to enable screening for multiple cancers from a single blood draw. By addressing the critical gap in early detection, Harbinger Health has the potential to significantly improve survival rates and reduce healthcare costs associated with late-stage cancer treatment.

Upcoming Catalysts (preview)

• Q3 2026Publication of clinical validation data from prospective study70% success
• H2 2026Partnership with major health system for pilot implementation60% success
• H1 2026FDA Breakthrough Device Designation80% success